# Sumitomo Pharma America, Inc. clinical trials: 181 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 181 trials with Sumitomo Pharma America, Inc. as lead sponsor, 5 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Sumitomo Pharma America, Inc.: 181 rows for $9.05, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/sumitomo-pharma-america-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 181
- Recruiting or not yet: 5
- Read on: November 19, 2026

## Trials

The 25 newest of 181, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| March 25, 2026 | NCT07492355 | TP-3654 Food Effect Study | Sumitomo Pharma America, Inc. | Phase 1 | Completed | Myelofibroses | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07492355) |
| March 2, 2026 | NCT07444268 | How \[14C\]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers | Sumitomo Pharma America, Inc. | Phase 1 | Completed | Advanced Hematologic Malignancies | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07444268) |
| March 24, 2025 | NCT06891885 | A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older... | Sumitomo Pharma America, Inc. | Phase 1/2 | Recruiting | Retinitis Pigmentosa | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06891885) |
| December 31, 2024 | NCT06753331 | A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease | Sumitomo Pharma America, Inc. | Phase 1/2 | Recruiting | Parkinson's Disease | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06753331) |
| July 30, 2024 | NCT06526819 | SMP-3124LP in Adults With Advanced Solid Tumors | Sumitomo Pharma America, Inc. | Phase 1/2 | Recruiting | Solid Tumor | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06526819) |
| July 24, 2024 | NCT06517940 | A Prospective, Observational Study in Adults With Retinitis Pigmentosa (RP) | Sumitomo Pharma America, Inc. | Observational | Active not recruiting | Retinitis Pigmentosa | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06517940) |
| April 29, 2024 | NCT06389955 | Assessment of Relative Bioavailability and Effect of Food on Capsule and Tablet Formulations of TP-3654 | Sumitomo Pharma America, Inc. | Phase 1 | Completed | Healthy | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06389955) |
| September 14, 2023 | NCT06037668 | A Randomized, Controlled Study of Two At-Home Self-Guided Virtual Reality Interventions for Adults With Social Anxiety Disorder. | Sumitomo Pharma America, Inc. | Not applicable | Completed | Social Anxiety Disorder (SAD) | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06037668) |
| November 4, 2022 | NCT05605964 | Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate | Sumitomo Pharma America, Inc. | Phase 3 | Completed | Prostate Cancer | 387 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05605964) |
| July 20, 2022 | NCT05467176 | A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX | Sumitomo Pharma America, Inc. | Observational | Completed | Prostate Cancer | 999 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05467176) |
| February 7, 2022 | NCT05227209 | A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode... | Sumitomo Pharma America, Inc. | Phase 3 | Terminated | Depressive Episodes, Bipolar I Depression | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05227209) |
| December 27, 2021 | NCT05169710 | A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder. | Sumitomo Pharma America, Inc. | Phase 3 | Terminated | Depressive Episodes, Bipolar I Depression | 83 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05169710) |
| August 26, 2021 | NCT05023551 | Study of DSP-0390 in Patients With Recurrent High-Grade Glioma | Sumitomo Pharma America, Inc. | Early phase 1 | Active not recruiting | High Grade Glioma, Glioblastoma Multiforme | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05023551) |
| August 3, 2021 | NCT04988555 | A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) | Sumitomo Pharma America, Inc. | Phase 1/2 | Recruiting | Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes | 606 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04988555) |
| December 14, 2020 | NCT04666129 | Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant... | Sumitomo Pharma America, Inc. | Phase 1 | Completed | Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer, Non-Metastatic... | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04666129) |
| November 10, 2020 | NCT04623996 | A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS | Sumitomo Pharma America, Inc. | Phase 1/2 | Terminated | Anemia in Myelodysplastic Syndromes | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04623996) |
| March 31, 2020 | NCT04328740 | Phase 1 Study of Oral TP-1454 | Sumitomo Pharma America, Inc. | Phase 1 | Completed | Advanced Solid Tumor, Anal Cancer | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04328740) |
| March 9, 2020 | NCT04299880 | Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols | Sumitomo Pharma America, Inc. | Phase 1 | Completed | Oncology | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04299880) |
| November 25, 2019 | NCT04176198 | A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis | Sumitomo Pharma America, Inc. | Phase 1/2 | Recruiting | Myelofibrosis | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04176198) |
| May 31, 2019 | NCT03969420 | Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy | Sumitomo Pharma America, Inc. | Phase 2 | Terminated | Acute Myeloid Leukemia (AML) | 11 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03969420) |
| October 23, 2018 | NCT03715504 | Study of TP-3654 in Patients With Advanced Solid Tumors | Sumitomo Pharma America, Inc. | Phase 1 | Completed | Advanced Solid Tumors | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03715504) |
| August 13, 2018 | NCT03627195 | A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia | Sumitomo Pharma America, Inc. | Phase 1 | Completed | Schizophrenia | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03627195) |
| July 27, 2018 | NCT03604783 | Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors | Sumitomo Pharma America, Inc. | Phase 1 | Terminated | Advanced Solid Tumors, Sarcoma, Ewing Sarcoma, Dedifferentiated Liposarcoma, Synovial Sarcoma | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03604783) |
| July 20, 2018 | NCT03593915 | A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS | Sumitomo Pharma America, Inc. | Phase 1/2 | Terminated | Myelodysplastic Syndromes (MDS) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03593915) |
| June 28, 2018 | NCT03572634 | Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL | Sumitomo Pharma America, Inc. | Phase 1/2 | Terminated | Chronic Lymphocytic Leukemia, CLL, SLL, Small Lymphocytic Lymphoma | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03572634) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 40 |
| Phase 1/2 | 14 |
| Phase 2 | 29 |
| Phase 2/3 | 2 |
| Phase 3 | 82 |
| Phase 4 | 8 |
| Not applicable | 1 |
| Observational | 4 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 153 |
| Terminated | 18 |
| Recruiting | 5 |
| Withdrawn | 3 |
| Active not recruiting | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Schizophrenia | 23 |
| Neoplasms | 22 |
| Asthma | 16 |
| Pulmonary Disease, Chronic Obstructive | 14 |
| Sleep Initiation and Maintenance Disorders | 12 |
| Depression | 10 |
| Attention Deficit Disorder with Hyperactivity | 10 |
| Bipolar Disorder | 8 |
| Rhinitis, Allergic, Perennial | 8 |
| Bronchitis, Chronic | 7 |
| Parkinson Disease | 7 |
| Leukemia, Myeloid, Acute | 7 |
| Epilepsy | 7 |
| Emphysema | 6 |
| Depressive Disorder, Major | 5 |
| Seizures | 5 |
| Glioblastoma | 4 |
| Wilms Tumor | 4 |
| Neoplasms by Site | 4 |
| Psychotic Disorders | 4 |
| Binge-Eating Disorder | 4 |
| Digestive System Neoplasms | 4 |
| Pancreatic Neoplasms | 4 |
| Ovarian Neoplasms | 4 |
| Myelodysplastic Syndromes | 3 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Agricultural cooperatives in the United States](https://specstream.ai/data/businesses/agricultural-cooperatives/united-states)
- [Vascular medicine practices in the United States](https://specstream.ai/data/businesses/vascular-medicine-practices/united-states)
- [Surgery practices in the United States](https://specstream.ai/data/businesses/surgery-practices/united-states)
- [Salvadoran restaurants in the United States](https://specstream.ai/data/businesses/salvadoran-restaurants/united-states)
- [Pressure washing companies in the United States](https://specstream.ai/data/businesses/pressure-washing-companies/united-states)
- [Otology practices in the United States](https://specstream.ai/data/businesses/otology-practices/united-states)
